GEO series

Lack of synergy between AR targeted therapies and PARP inhibition in homologous recombination- proficient prostate cancer

GSE315878 Homo sapiens (human) RNA-seq (gene expression) 70 samples Submitted 2026/01/13 Platform GPL34281

At a glance

RNA-seq (gene expression) · human · 70 samples

What it is: RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism: Homo sapiens (human)
Topic: Prostate cancerThis series is part of our curated briefing on it.
Samples: 70 samples: 35 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
Data you can get: A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper: Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancerProceedings of the National Academy of Sciences of the United States of America · 2026

Summary (written by the submitters)

Recent clinical trials have explored the combination of androgen receptor (AR) pathway inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors as a potential treatment for castration-resistant prostate cancer. This combination treatment is based on the premise that AR directly regulates expression of DNA repair genes, leading to synergy between PARP and AR inhibition.

Read the full summary ↓

Despite some promising preclinical evidence, this combination therapy has shown limited efficacy in patients with homologous recombination (HR)-proficient tumors. To investigate this discrepancy between preclinical and clinical results, we profiled the effects of PARP inhibition in prostate cancer models in the presence or absence of AR inhibition. Surprisingly, AR inhibition impaired response to PARP inhibitors in castration-sensitive cells and had no effect on response in castration-resistant cells. AR inhibition also did not regulate DNA repair in either the castration-resistant or castration-sensitive setting. Instead, we find that cell cycle progression is required for response to PARP inhibition in homologous-recombination proficient prostate cancer.

Published in

Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer

Traphagen NA, Wheeler E, Li R et al. · Proceedings of the National Academy of Sciences of the United States of America 2026 · PMID 41591905 · doi:10.1073/pnas.2515790122

This dataset

Open GSE315878 in finder → Find more human RNA-seq datasets → Prostate cancer landscape →

Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE315878_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓

3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1399478 and SRA study SRP660488. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 41591905) ↗

Study design

35 conditions, mostly in duplicate

22RV1, ADT, ×2 22RV1, DHT 4h, ×2 22RV1, DHT 16h, ×2 22RV1, ADT, Olaparib, ×2 22RV1, DHT 4 h, Olaparib, ×2 22RV1, DHT 16 h, Olaparib, ×2 22RV1, ADT, Rucaparib, ×2 22RV1, DHT 4 h, Rucaparib, ×2 +27 more

Supports a between-group comparison across 70 samples.

How we read this: 35 replicated groups read from 70 sample titles; they account for 70 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study

GSM9438988 22RV1, ADT, Rep1 22RV1, ADT,
GSM9438989 22RV1, DHT 4h, Rep1 22RV1, DHT 4h,
GSM9438990 22RV1, DHT 16h, Rep1 22RV1, DHT 16h,
GSM9438991 22RV1, ADT, Olaparib, Rep1 22RV1, ADT, Olaparib,
GSM9438992 22RV1, DHT 4 h, Olaparib, Rep1 22RV1, DHT 4 h, Olapari…
GSM9438993 22RV1, DHT 16 h, Olaparib, Rep1 22RV1, DHT 16 h, Olapar…
GSM9438994 22RV1, ADT, Rucaparib, Rep1 22RV1, ADT, Rucaparib,
GSM9438995 22RV1, DHT 4 h, Rucaparib, Rep1 22RV1, DHT 4 h, Rucapar…
GSM9438996 22RV1, DHT 16 h, Rucaparib, Rep1 22RV1, DHT 16 h, Rucapa…
GSM9438997 22RV1, ADT, AZD5305, Rep1 22RV1, ADT, AZD5305,
GSM9438998 22RV1, DHT 4 h, AZD5305, Rep1 22RV1, DHT 4 h, AZD5305,
GSM9438999 22RV1, DHT 16 h, AZD5305, Rep1 22RV1, DHT 16 h, AZD530…
GSM9439000 22RV1, ADT, Rep2 22RV1, ADT,
GSM9439001 22RV1, DHT 4h, Rep2 22RV1, DHT 4h,
GSM9439002 22RV1, DHT 16h, Rep2 22RV1, DHT 16h,
GSM9439003 22RV1, ADT, Olaparib, Rep2 22RV1, ADT, Olaparib,
GSM9439004 22RV1, DHT 4 h, Olaparib, Rep2 22RV1, DHT 4 h, Olapari…
GSM9439005 22RV1, DHT 16 h, Olaparib, Rep2 22RV1, DHT 16 h, Olapar…
GSM9439006 22RV1, ADT, Rucaparib, Rep2 22RV1, ADT, Rucaparib,
GSM9439007 22RV1, DHT 4 h, Rucaparib, Rep2 22RV1, DHT 4 h, Rucapar…
GSM9439008 22RV1, DHT 16 h, Rucaparib, Rep2 22RV1, DHT 16 h, Rucapa…
GSM9439009 22RV1, ADT, AZD5305, Rep2 22RV1, ADT, AZD5305,
GSM9439010 22RV1, DHT 4 h, AZD5305, Rep2 22RV1, DHT 4 h, AZD5305,
GSM9439011 22RV1, DHT 16 h, AZD5305, Rep2 22RV1, DHT 16 h, AZD530…
GSM9439012 LNCaP, ADT, Rep1 LNCaP, ADT,
GSM9439013 LNCaP, DHT 4h, Rep1 LNCaP, DHT 4h,
GSM9439014 LNCaP, DHT 16h, Rep1 LNCaP, DHT 16h,
GSM9439015 LNCaP, ADT, Olaparib, Rep1 LNCaP, ADT, Olaparib,
GSM9439016 LNCaP, DHT 4 h, Olaparib, Rep1 LNCaP, DHT 4 h, Olapari…
GSM9439017 LNCaP, DHT 16 h, Olaparib, Rep1 LNCaP, DHT 16 h, Olapar…
GSM9439018 LNCaP, ADT, Rucaparib, Rep1 LNCaP, ADT, Rucaparib,
GSM9439019 LNCaP, DHT 16 h, Rucaparib, Rep1 LNCaP, DHT 16 h, Rucapa…
GSM9439020 LNCaP, ADT, AZD5305, Rep1 LNCaP, ADT, AZD5305,
GSM9439021 LNCaP, DHT 4 h, AZD5305, Rep1 LNCaP, DHT 4 h, AZD5305,
GSM9439022 LNCaP, DHT 16 h, AZD5305, Rep1 LNCaP, DHT 16 h, AZD530…
GSM9439023 LNCaP, ADT, Rep2 LNCaP, ADT,
GSM9439024 LNCaP, DHT 4h, Rep2 LNCaP, DHT 4h,
GSM9439025 LNCaP, DHT 16h, Rep2 LNCaP, DHT 16h,
GSM9439026 LNCaP, ADT, Olaparib, Rep2 LNCaP, ADT, Olaparib,
GSM9439027 LNCaP, DHT 4 h, Olaparib, Rep2 LNCaP, DHT 4 h, Olapari…

+ 30 more — browse all 70 samples with per-sample file links →

More Prostate cancer datasets

GSE115501 RNA sequencing on circulating tumor cells from prostate cancer patients 136 samples same disease briefing · shares prostate
GSE222467 The RNA binding proteins LARP4A and LARP4B promote tumour growth and metastasis in prostate cancer and osteosarcoma 12 samples same disease briefing · shares prostate
GSE300947 A novel six-biomarker panel identified from male breast cancer-associated fibroblasts demonstrates prognostic power for prostate tumors 6 samples same disease briefing · shares prostate
GSE120181 Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment 2 samples same disease briefing · shares prostate
GSE242541 ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity 12 samples same disease briefing
GSE71008 Plasma extracellular RNA profiles in healthy and cancer patients 192 samples same disease briefing
GSE222556 Neoadjuvant PARPi or Chemotherapy in Ovarian Cancer Informs Targeting Effector Treg Cells for Homologous-Recombination-Deficient Tumors [10x scRNA-seq] 67 samples shares parp, recombination, homologous
GSE322615 Investigating response to PARP inhibition and androgen receptor pathway inhibition in C4-2B prostate cancer cells 39 samples shares parp, inhibition, prostate

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.